This is an aggregated industry headline. Read the full story at BioPharma Dive →
Novartis RNA drug acquired in $12B Avidity deal notches a trial win
The data showed that del-brax, an "antisense oligonucleotide conjugate" being tested against a muscle-wasting disease, met its primary endpoint in a Phase 1/2 study.
By BioPharma Dive
· Jun 11, 2026
· via BioPharma Dive
Image: BioPharma Dive
RxInsider combines reported facts with industry analysis and informed inference. Forward-looking reads, market commentary, and interpretive framing reflect analysis of available reporting and known facts, not confirmed outcomes.
Tags
theweekformat:headlineheadlineBioPharma Dive
The Insider - Weekly pharma intelligence
Deals, negotiations, and policy analysis. Delivered when it matters.
No sponsored content. No noise. Unsubscribe anytime.
More from The Week
All The Week →
The WeekFiercePharma ↗
In this tracker, Fierce Pharma is recording the regulatory progress of in-market products, including expansion…
The WeekFierceBiotech ↗
Staring down a $6 billion patent cliff for its prostate cancer drug Xtandi, Astellas aims to counter the inevi…
The WeekBriefing
STAT News spotlighted obesity drugs in development, peptide therapies going mainstream, and a record biotech I…